← Oncology Approval Tracker

FDA DECISION ·

Onivyde + oxaliplatin + fluorouracil + leucovorin

irinotecan liposome with oxaliplatin, fluorouracil and leucovorin · Ipsen Biopharmaceuticals

FDA approvalNew or expanded indicationPancreatic cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of metastatic pancreatic adenocarcinoma with liposomal irinotecan, oxaliplatin, fluorouracil and leucovorin.

LAMPGEN ANALYSIS

Why it matters

The NALIRIFOX regimen added a first-line liposomal irinotecan-based option supported by a head-to-head trial.

What research teams should watch

Clearly identify the liposomal product in orders and coordinate diarrhea plans, laboratory review and infusion pump handoffs.

PRIMARY RECORDS

Sources